Development and validation of a prediction model for frailty in breast cancer patients with extended survival. 2024

Shurui Wang, and Difei Huang, and Xiaofeng Liu, and Qiang Tang, and Chenxi Xi, and Yixin Ma, and Huan Liu, and Xing Chen, and Aomei Shen, and Maojun Di, and Wanmin Qiang, and Xian Du
Department of General Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, Hubei Province, People's Republic of China.

BACKGROUND Breast cancer (BC) patients with extended survival show a higher incidence of frailty. This study aimed to develop and validate a novel model combining sociodemographic factors (SF) and disease-related factors (DRF) to identify frailty in BC patients with extended survival. METHODS This cross-sectional study examined data from 1167 patients admitted to a large urban academic medical centre. Three types of predictive models were constructed in the training set (817 patients): the SF model, the DRF model, and the SF + DRF model (combined model). The model performance and effectiveness were assessed using receiver operating characteristic (ROC) curves, calibration plots and decision curves analysis (DCA). Then the model was subsequently validated on the validation set. RESULTS The incidence of frailty in BC patients with extended survival was 35.8%. We identified six independent risk factors including age, health status, chemotherapy, endocrine therapy, number of comorbidities and oral medications. Ultimately, we constructed an optimal model (combined model C) for frailty. The predictive model showed significantly high discriminative accuracy in the training set AUC: 0.754, (95% CI, 0.719-0.789; sensitivity: 76.8%, specificity: 62.2%) and validation set AUC: 0.805, (95% CI, 0.76-0.85), sensitivity: 60.8%, specificity: 87.1%) respectively. A prediction nomogram was constructed for the training and validation sets. Calibration and DCA were performed, which indicated that the clinical model presented satisfactory calibration and clinical utility. Ultimately, we implemented the prediction model into a mobile-friendly web application that provides an accurate and individualized prediction for BC. CONCLUSIONS The present study demonstrated that the prevalence of frailty in BC patients with extended survival was 35.8%. We developed a novel model for screening frailty, which may provide evidence for frailty screening and prevention.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000073496 Frailty A state of increased vulnerability to stressors, following declines in function and reserves across multiple physiologic systems, characterized by MUSCLE WEAKNESS; FATIGUE; slowed motor performance; low physical activity; and unintentional weight loss. Debility,Frailness,Frailty Syndrome,Debilities,Frailties
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor

Related Publications

Shurui Wang, and Difei Huang, and Xiaofeng Liu, and Qiang Tang, and Chenxi Xi, and Yixin Ma, and Huan Liu, and Xing Chen, and Aomei Shen, and Maojun Di, and Wanmin Qiang, and Xian Du
March 2023, BMC geriatrics,
Shurui Wang, and Difei Huang, and Xiaofeng Liu, and Qiang Tang, and Chenxi Xi, and Yixin Ma, and Huan Liu, and Xing Chen, and Aomei Shen, and Maojun Di, and Wanmin Qiang, and Xian Du
November 2019, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi,
Shurui Wang, and Difei Huang, and Xiaofeng Liu, and Qiang Tang, and Chenxi Xi, and Yixin Ma, and Huan Liu, and Xing Chen, and Aomei Shen, and Maojun Di, and Wanmin Qiang, and Xian Du
November 2020, Annals of translational medicine,
Shurui Wang, and Difei Huang, and Xiaofeng Liu, and Qiang Tang, and Chenxi Xi, and Yixin Ma, and Huan Liu, and Xing Chen, and Aomei Shen, and Maojun Di, and Wanmin Qiang, and Xian Du
October 2022, Clinical breast cancer,
Shurui Wang, and Difei Huang, and Xiaofeng Liu, and Qiang Tang, and Chenxi Xi, and Yixin Ma, and Huan Liu, and Xing Chen, and Aomei Shen, and Maojun Di, and Wanmin Qiang, and Xian Du
January 2024, Aging clinical and experimental research,
Shurui Wang, and Difei Huang, and Xiaofeng Liu, and Qiang Tang, and Chenxi Xi, and Yixin Ma, and Huan Liu, and Xing Chen, and Aomei Shen, and Maojun Di, and Wanmin Qiang, and Xian Du
October 2023, Journal of cancer research and clinical oncology,
Shurui Wang, and Difei Huang, and Xiaofeng Liu, and Qiang Tang, and Chenxi Xi, and Yixin Ma, and Huan Liu, and Xing Chen, and Aomei Shen, and Maojun Di, and Wanmin Qiang, and Xian Du
October 2022, Journal of gastrointestinal oncology,
Shurui Wang, and Difei Huang, and Xiaofeng Liu, and Qiang Tang, and Chenxi Xi, and Yixin Ma, and Huan Liu, and Xing Chen, and Aomei Shen, and Maojun Di, and Wanmin Qiang, and Xian Du
November 2022, Cancers,
Shurui Wang, and Difei Huang, and Xiaofeng Liu, and Qiang Tang, and Chenxi Xi, and Yixin Ma, and Huan Liu, and Xing Chen, and Aomei Shen, and Maojun Di, and Wanmin Qiang, and Xian Du
September 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,
Shurui Wang, and Difei Huang, and Xiaofeng Liu, and Qiang Tang, and Chenxi Xi, and Yixin Ma, and Huan Liu, and Xing Chen, and Aomei Shen, and Maojun Di, and Wanmin Qiang, and Xian Du
January 2021, Frontiers in endocrinology,
Copied contents to your clipboard!